A detailed history of Exchange Traded Concepts, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Exchange Traded Concepts, LLC holds 43,813 shares of EXEL stock, worth $984,478. This represents 0.03% of its overall portfolio holdings.

Number of Shares
43,813
Previous 118,359 62.98%
Holding current value
$984,478
Previous $2.84 Million 63.4%
% of portfolio
0.03%
Previous 0.08%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 15, 2024

SELL
$20.17 - $23.93 $1.5 Million - $1.78 Million
-74,546 Reduced 62.98%
43,813 $1.04 Million
Q4 2023

Jan 05, 2024

BUY
$19.25 - $24.13 $1.62 Million - $2.03 Million
83,999 Added 244.47%
118,359 $2.84 Million
Q3 2023

Oct 18, 2023

SELL
$19.04 - $22.74 $189,086 - $225,830
-9,931 Reduced 22.42%
34,360 $750,000
Q2 2023

Jul 20, 2023

BUY
$18.17 - $20.48 $119,867 - $135,106
6,597 Added 17.5%
44,291 $846,000
Q1 2023

Apr 12, 2023

BUY
$16.3 - $19.41 $63,292 - $75,369
3,883 Added 11.48%
37,694 $731,000
Q4 2022

Jan 17, 2023

BUY
$14.96 - $17.39 $8,437 - $9,807
564 Added 1.7%
33,811 $542,000
Q3 2022

Oct 07, 2022

BUY
$15.68 - $22.27 $521,312 - $740,410
33,247 New
33,247 $521,000
Q3 2021

Oct 18, 2021

SELL
$16.3 - $21.14 $387,092 - $502,032
-23,748 Closed
0 $0
Q2 2021

Jul 30, 2021

BUY
$17.95 - $25.56 $66,450 - $94,623
3,702 Added 18.47%
23,748 $433,000
Q1 2021

Apr 20, 2021

BUY
$20.53 - $25.22 $105,832 - $130,009
5,155 Added 34.62%
20,046 $453,000
Q4 2020

Jan 19, 2021

BUY
$18.39 - $24.8 $12,468 - $16,814
678 Added 4.77%
14,891 $299,000
Q3 2020

Oct 30, 2020

BUY
$20.67 - $26.94 $45,908 - $59,833
2,221 Added 18.52%
14,213 $348,000
Q2 2020

Jul 15, 2020

BUY
$16.46 - $27.42 $197,388 - $328,820
11,992 New
11,992 $285,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $7.23B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Exchange Traded Concepts, LLC Portfolio

Follow Exchange Traded Concepts, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exchange Traded Concepts, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Exchange Traded Concepts, LLC with notifications on news.